[go: up one dir, main page]

PE20010052A1 - Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht - Google Patents

Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht

Info

Publication number
PE20010052A1
PE20010052A1 PE2000000368A PE0003682000A PE20010052A1 PE 20010052 A1 PE20010052 A1 PE 20010052A1 PE 2000000368 A PE2000000368 A PE 2000000368A PE 0003682000 A PE0003682000 A PE 0003682000A PE 20010052 A1 PE20010052 A1 PE 20010052A1
Authority
PE
Peru
Prior art keywords
alkyl
aryl
azepinindol
agonists
antagonists
Prior art date
Application number
PE2000000368A
Other languages
English (en)
Inventor
Jackson B Hester Jr
Bruce N Rogers
Eric Jon Jacobsen
Michael Dalton Ennis
Kristine E Frank
Velde Susan L Vander
Brad A Acker
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of PE20010052A1 publication Critical patent/PE20010052A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A DERIVADOS DE 1,2,3,4,5,6-HEXAHIDROAZEPIN-[4,5-b]INDOL QUE TIENEN UN ANILLO PARA UNIR LA POSICION 6 Y 7 DE FORMULA I DONDE R1 ES OH, NITRO, HALOGENO, CN, TRIFLUOROMETILO, S(O)mNRaRb, NRcRd, S(O)mRe, ENTRE OTROS; R2 ES H, ALQUILO C1-C7, ALCANOILO C1-C7, ALCOXICARBONILO C1-C7, ENTRE OTROS; X E Y JUNTOS SON UNA CADENA CON ATOMOS DE C OPCIONALMENTE CONTIENE UN GRUPO -O-, -S-, -SO-, -SO2-, NRf OPCIONALMENTE SUSTITUIDA CON OXO, OH, ALCOXILO C1-C7; m ES 0-2; n ES 0-3; CADA Ra Y Rb SON H, ALQUILO C1-C7, ARILO, ARILALQUILO C1-C7, HETEROARILO, HETEROARIL ALQUILO C1-C7; Ra Y Rb JUNTO CON N FORMAN PIRROLIDINO, PIPERIDINO, MORFOLINO, TIOMORFOLINO; CADA Rc Y Rd SON H, ALQUILO C1-C7, ALCANOILO C1-C7, ALCOXICARBONILO C1-C7, ARILO, O JUNTO CON N FORMAN PIRROLIDINO, PIPERIDINO, MORFOLINO, TIOMORFOLINO, ENTRE OTROS; Re ES H, ALQUILO C1-C7, ARILO, ENTRE OTROS; Rf ES H, ALQUILO C1-C7, ARILO, ARILALQUILO C1-C7, ENTRE OTROS; CON LA CONDICION QUE Y NO ES OXI, TIO, SULFINILO, NRf, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 5,6,9,10,11,12-HEXAHIDRO-4H,8H-AZEPIN[4`,5':4,5]PIRROL[3,2,1-ij]QUINOLINA, 2-METIL-5,6,9,10,11,12-HEXAHIDRO-4H,8H-AZEPIN[4',5':4,5]PIRROL[3,2,1-ij]-QUINOLINA, ENTRE OTROS. LOS COMPUESTOS I SON LIGANDOS DE SEROTONINA 5-HT Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL, SUENO, DEPRESION
PE2000000368A 1999-04-23 2000-04-19 Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht PE20010052A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13081199P 1999-04-23 1999-04-23

Publications (1)

Publication Number Publication Date
PE20010052A1 true PE20010052A1 (es) 2001-01-27

Family

ID=22446459

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000368A PE20010052A1 (es) 1999-04-23 2000-04-19 Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht

Country Status (20)

Country Link
EP (1) EP1173440B1 (es)
JP (1) JP2002543080A (es)
KR (1) KR20020005708A (es)
CN (1) CN1183132C (es)
AR (1) AR023574A1 (es)
AT (1) ATE276255T1 (es)
AU (1) AU760943C (es)
BR (1) BR0009983A (es)
CA (1) CA2367682A1 (es)
DE (1) DE60013803T2 (es)
DK (1) DK1173440T3 (es)
EC (1) ECSP003426A (es)
ES (1) ES2226822T3 (es)
HK (1) HK1045512B (es)
NZ (1) NZ514553A (es)
PE (1) PE20010052A1 (es)
PT (1) PT1173440E (es)
SI (1) SI1173440T1 (es)
WO (1) WO2000064899A1 (es)
ZA (1) ZA200108636B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
MXPA01012969A (es) 1999-06-15 2003-10-14 Bristol Myers Squibb Pharma Co Gamma-carbolinas fusionadas de heterociclo sustituido.
WO2002004456A1 (en) 2000-07-06 2002-01-17 Pharmacia & Upjohn Company SUBSTITUTED 2,3,7,8,9,10,11,12-OCTAHYDROAZEPINO[4,5-b]PYRANO[3,2-e]INDOLES
AR034264A1 (es) 2000-09-20 2004-02-18 Upjohn Co Derivados azepino(4,5-b)indol sustituidos y composiciones farmaceuticas
AR031202A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
AR031199A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
AR031200A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
RU2003121304A (ru) 2000-12-20 2005-01-27 Бристол-Маерс Сквибб Компани (Us) Замещенные пиридоиндолы в качестве агонистов и антагонистов серотонина
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
US20020160999A1 (en) * 2001-01-08 2002-10-31 Jacobsen Susan Fox Substituted indolines
US20030060462A1 (en) * 2001-08-06 2003-03-27 Hoffman Robert L. Therapeutic compounds
MXPA04001202A (es) * 2001-08-06 2005-02-17 Pharmacia & Upjhon Company Ligandos tetraciclicos terapeuticamente utiles.
WO2003024976A2 (en) * 2001-09-21 2003-03-27 Pharmacia & Upjohn Company Tricyclic indole derivatives as 5-ht ligands
CA2464412A1 (en) 2001-10-18 2003-04-24 Pharmacia & Upjohn Company Tetracyclic azaindoles and -indolines having serotonin 5-ht2cactivity
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
US8685924B2 (en) 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
CA2636992C (en) * 2006-01-19 2015-10-06 Athersys, Inc. Thiophenyl and pyrrolyl azepines as serotonin 5-ht2c receptor ligands and uses thereof
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
KR102372149B1 (ko) 2007-03-12 2022-03-07 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
CA2727055C (en) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
EP2421870B1 (en) * 2009-04-23 2016-03-09 AbbVie Inc. Modulators of 5-ht receptors and methods of use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
EP2448585B1 (en) 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
JP2015514135A (ja) 2012-04-14 2015-05-18 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
PT2968320T (pt) 2013-03-15 2021-01-28 Intra Cellular Therapies Inc Compostos orgânicos
JP6475727B2 (ja) 2013-12-03 2019-02-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規方法
HUE065482T2 (hu) 2014-04-04 2024-05-28 Intra Cellular Therapies Inc Deuterált heterociklus-fúzionált gamma-karbolinok mint 5-HT2A receptorok antagonistái
EP3125892A4 (en) 2014-04-04 2017-12-27 Intra-Cellular Therapies, Inc. Organic compounds
PL3838274T3 (pl) 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
WO2017172784A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel salts and crystals
JP6997718B2 (ja) 2016-03-28 2022-01-18 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規共結晶
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
CN105837571A (zh) * 2016-04-23 2016-08-10 何华琼 盐酸倍他司汀的药物组合物及其在生物医药中的应用
US12343337B2 (en) 2016-09-29 2025-07-01 The Regents Of The University Of California Compounds for increasing neural plasticity
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
US10906906B2 (en) 2016-12-29 2021-02-02 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018175969A1 (en) 2017-03-24 2018-09-27 Intra-Cellular Therapies, Inc. Novel compositions and methods
AU2018307479B2 (en) 2017-07-26 2024-06-20 Intra-Cellular Therapies, Inc. Organic compounds
US11427587B2 (en) 2017-07-26 2022-08-30 Intra-Cellular Therapies, Inc. Organic compounds
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
CN119613404A (zh) 2018-03-23 2025-03-14 细胞内治疗公司 有机化合物
IL279195B1 (en) 2018-06-06 2025-08-01 Intra Cellular Therapies Inc A method of making bis-tosylate salt of lumateparone
WO2019237037A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
CA3106447A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
JP2022500362A (ja) 2018-08-29 2022-01-04 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規組成物および方法
KR20210052472A (ko) 2018-08-31 2021-05-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
BR112021003655A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
CN113227045B (zh) 2018-12-17 2024-04-26 细胞内治疗公司 取代的杂环稠合的γ-咔啉的合成
JP7520013B2 (ja) 2018-12-17 2024-07-22 イントラ－セルラー・セラピーズ・インコーポレイテッド 置換複素環縮合γ－カルボリンの合成
WO2020176599A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California Azepino-indoles and other heterocycles for treating brain disorders
AU2020311894B2 (en) 2019-07-07 2025-06-26 Intra-Cellular Therapies, Inc. Novel methods
JP7261942B2 (ja) 2019-12-11 2023-04-20 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
TW202333668A (zh) 2021-12-15 2023-09-01 美商德利克斯醫療公司 經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839357A (en) * 1966-05-10 1974-10-01 Upjohn Co 1,2,3,4,5,6-hexahydroazepino(4,5-b)indoles
US3676558A (en) * 1970-08-28 1972-07-11 Upjohn Co Anorexigenic compositions comprising 6-alkyl-1,2,3,4,5,6-hexahydroazepino 4,5-indoles as active ingredient and process of treatment
EP0377238A1 (en) * 1988-12-22 1990-07-11 Duphar International Research B.V New annelated indolo (3,2-c)-lactams

Also Published As

Publication number Publication date
ECSP003426A (es) 2000-10-24
AU760943C (en) 2003-12-04
NZ514553A (en) 2003-10-31
BR0009983A (pt) 2002-04-16
CA2367682A1 (en) 2000-11-02
AU760943B2 (en) 2003-05-22
DE60013803T2 (de) 2005-11-17
DK1173440T3 (da) 2004-12-20
CN1348454A (zh) 2002-05-08
ZA200108636B (en) 2003-02-19
PT1173440E (pt) 2004-12-31
EP1173440A1 (en) 2002-01-23
AU4363700A (en) 2000-11-10
ES2226822T3 (es) 2005-04-01
HK1045512A1 (en) 2004-10-15
KR20020005708A (ko) 2002-01-17
CN1183132C (zh) 2005-01-05
SI1173440T1 (en) 2005-02-28
DE60013803D1 (de) 2004-10-21
WO2000064899A1 (en) 2000-11-02
HK1045512B (zh) 2005-09-02
AR023574A1 (es) 2002-09-04
EP1173440B1 (en) 2004-09-15
JP2002543080A (ja) 2002-12-17
ATE276255T1 (de) 2004-10-15

Similar Documents

Publication Publication Date Title
PE20010052A1 (es) Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht
Chu et al. Structure-activity relationships of the fluoroquinolones
Katritzky et al. Synthesis of heterocycles mediated by benzotriazole. 2. Bicyclic systems
RU2496775C2 (ru) Соединение бензодиазепина и фармацевтическая композиция
PE20090718A1 (es) Derivados de espiroindolinona
PE20030848A1 (es) Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1
AR061867A1 (es) Derivados de (4,5') bipirimidil 6,4' - diamina como inhibidores de proteinquinasa
JP6843979B2 (ja) 新規なビフェニル化合物又はその塩
AR043180A1 (es) Derivados de heterociclil-3-sulfonilazaindol o -azaindazol como ligandos de 5-hidroxitriptamina-6
PE20110671A1 (es) Derivados de diazabicicloalcanos como moduladores de la actividad de los receptores nicotinicos de la acetilcolina
KR920701204A (ko) 중추 신경계 활성을 갖는 헤테로사이클릭 아민
AR035666A1 (es) Imidazo[4,5-c]quinolin-4-aminas y tetrahidroimidazo[4,5-c]quinolin-4-aminas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
AR067662A1 (es) Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso.
PE20040593A1 (es) DERIVADOS DE DIHIDROPIRIMIDO[4,5-d]PIRIMIDONA AMINO SUSTITUIDOS COMO INHIBIDORES DE TIROSINACINASAS DEL GRUPO SRC
AR029454A1 (es) Derivados de piperazina sustituidos, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos
PE20080403A1 (es) Derivados heterociclicos fusionados y metodos de uso
PE20020485A1 (es) Derivados de quinolina y quinazolina como antagonistas del neuropeptido y
AR045762A1 (es) Derivados de quinazolina
BR0309463A (pt) Derivados de 1,2,3,4,7,8-hexaidro-6h-[1,4]diazepino[6,7,1-ij]quinolina como agentes antipsicóticos e antiobesidade
AR031830A1 (es) Uso de un compuesto benzotiazinona o benzoxazinona para preparar una composicion farmaceutica, compuesto de benzotiazinona o benzoxazinona y composicion farmaceutica que lo comprende
PE20060383A1 (es) Nuevos derivados amino de urea ciclicos como inhibidores de quinasa
AR043181A1 (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxiptamina-6
AR052312A1 (es) 2- anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y medicamentos preparados en base al compuesto
AR017189A1 (es) Antagonistas del receptor de trombina triciclico sustituido, composicion farmaceutica que lo contiene y su uso para la manufactura de un medicamento
PE20001537A1 (es) 4-alquenil y 4-alquinil oxindoles como inhibidores de quinasas dependientes de ciclina

Legal Events

Date Code Title Description
FC Refusal